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Most pain in cancer responds to pharmacological management using
orally administered analgesics and adjuvants. Current treatment is
based on the World Health Organization (WHO)’s concept of an
‘analgesic ladder’ which involves a stepwise approach to the use of
analgesic drugs and is essentially a framework of principles rather
than a rigid protocol (WHO, 1996). This allows considerable flex-
ibility in the choice of specific drugs and the WHO ladder should be
regarded as but one part of a comprehensive strategy for managing
cancer pain. Symptomatic drug treatment is used in an integrated
way with disease-modifying therapy and non-drug measures. 
The most important part of the WHO method, and the reason for
its success, is the efficient use of oral opioids for moderate to
severe pain. Morphine is the benchmark ‘step 3’ opioid and in
1996 we published guidelines for the use of this drug in cancer
pain management (Expert Working Group of the EAPC, 1996).
Since our earlier publication, a number of alternatives to morphine
have become available though these are generally not new mo-
lecules but novel formulations of existing drugs. There are few
randomized controlled trials (RCTs) involving head to head
comparisons between different opioids and this may make it dif-
ficult to choose the most appropriate drug for specific situations. 
In view of the paucity of RCT data the European Association
for Palliative Care’s Expert Working Group on Opioid Analgesics
has revised its recommendations for the use of morphine in cancer
pain and extended them to cover the use of alternative opioids
(Table 1). The strength of the evidence supporting each recom-
mendation is indicated (Table 2). 
1. The opioid of first choice for moderate to severe
cancer pain is morphine  C
Morphine is the standard ‘step 3’ opioid analgesic against which
others are measured and is the most widely available in a variety of
oral formulations. Morphine appears to have no clinically relevant
ceiling effect to analgesia: doses of oral morphine may vary 1000-
fold or more to achieve the same end point of pain relief. 
Unfounded fears associated with morphine 
Morphine has long been feared by both the general public and physi-
cians (Lasagna, 1965). Underlying the fear is the mistaken belief
that the problems associated with abuse of opioids are inextricably
linked to therapeutic use. Concerns about addiction, excessive seda-
tion, and respiratory depression have resulted in widespread avoid-
ance or under-dosing. Yet extensive, carefully documented clinical
experience has shown that these fears are unfounded (McQuay,
1999). Regular doses of morphine may be indicated and safely insti-
tuted early in the course of a patient’s illness and continued for many
months. Patients treated with morphine whose pain ameliorates can
reduce the dose and discontinue it without difficulty. 
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http://www.bjcancer.comDaytime drowsiness, dizziness or mental clouding commonly
occur at the start of treatment but resolve when patients are 
stabilized (usually within a few days). For most patients receiving
stable doses of morphine effects on cognitive and psychomotor
function are minimal. In particular, there are data indicating that
patients’ driving ability is not significantly impaired, in alert
patients receiving a stable dose (Vainio et al, 1995). Similarly,
nausea and vomiting, which occur in up to two-thirds of patients
when morphine is started, usually resolve. The main continuing
adverse effect from morphine is constipation, and the prophylactic
use of a laxative is almost always required. 
Morphine: limitations 
The systemic availability of morphine by the oral route is poor
(20–30%) and this contributes to a sometimes unpredictable onset
of action and great interindividual variability in dose requirements
and response (Glare and Walsh, 1991). Active metabolites may
contribute to toxicity, particularly in patients with renal impair-
ment (McQuay and Moore, 1997). And some types of pain do not
always respond well or completely to morphine, notably neuro-
pathic pain. However, none of the alternatives to morphine has so
far demonstrated advantages which would make it preferable as
the first line oral opioid for cancer pain. Morphine remains our
first choice but for reasons of familiarity, availability and cost
rather than proven superiority. 
2. The optimal route of administration of morphine is
by mouth. Ideally, two types of formulation are
required: normal release (for dose titration) and
modified release (for maintenance treatment)  C
The oral route is the simplest and most acceptable to patients.
There is large interindividual variation in kinetics (Säwe, 1986)
and dynamics in cancer patients whose pain will also vary in
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1. The opioid of first choice for moderate to severe cancer pain is morphine.
C
2. The optimal route of administration of morphine is by mouth. Ideally, two
types of formulation are required: normal release (for dose titration) and
modified release (for maintenance treatment). C
3. The simplest method of dose titration is with a dose of normal release
morphine given every 4 hours and the same dose for breakthrough pain.
This ‘rescue’ dose may be given as often as required (up to hourly) and
the total daily dose of morphine should be reviewed daily. The regular
dose can then be adjusted to take into account the total amount of rescue
morphine. C
4. If pain returns consistently before the next regular dose is due the regular
dose should be increased. In general, normal release morphine does not
need to be given more often than every 4 hours and modified release
morphine more often than 12 or 24 hours (according to the intended
duration of the formulation). Patients stabilized on regular oral morphine
require continued access to a rescue dose to treat ‘breakthrough’ pain. A
5. Several countries do not have a normal release formulation of morphine,
though such a formulation is necessary for optimal pain management. A
different strategy is needed if treatment is started with modified release
morphine. Changes to the regular dose should not be made more
frequently than every 48 hours, which means that the dose titration phase
will be prolonged. C
6. For patients receiving normal release morphine every 4 hours, a double
dose at bedtime is a simple and effective way of avoiding being woken by
pain. C
7. Several modified release formulations are available. There is no evidence
that the 12-hourly formulations (tablets, capsules or liquids) are
substantially different in their duration of effect and relative analgesic
potency. The same is true for the 24-hour formulations though there is
less evidence to draw on. A
8. If patients are unable to take morphine orally the preferred alternative
route is subcutaneous. There is generally no indication for giving
morphine intramuscularly for chronic cancer pain because subcutaneous
administration is simpler and less painful. C
9. The average relative potency ratio of oral morphine to subcutaneous
morphine is between 1:2 and 1:3 (i.e. 20–30 mg of morphine by mouth is
equianalgesic to 10 mg by s.c. injection). C
10. In patients requiring continuous parenteral morphine, the preferred
method of administration is by subcutaneous infusion. C
11. Intravenous infusion of morphine may be  preferred in patients: 
a. who already have an in-dwelling intravenous line;
b. with generalized oedema; 
c. who develop erythema, soreness or sterile abscesses with
subcutaneous administration; 
d. with coagulation disorders;
e. with poor peripheral circulation. C
12. The average relative potency ratio of oral to intravenous morphine is
between 1:2 and 1:3. A
13. The buccal, sublingual and nebulized routes of administration of
morphine are not recommended because at the present time there is no
evidence of clinical advantage over the conventional routes. B
14. Oral transmucosal fentanyl citrate (OTFC) is an effective treatment for
‘breakthrough pain’ in patients stabilized on regular oral morphine or an
alternative step 3 opioid. A
15. Successful pain management with opioids requires that adequate
analgesia be achieved without excessive adverse effects. By these
criteria the application of the WHO and the EAPC guidelines (using
morphine as the preferred step 3 opioid) permit effective control of
chronic cancer pain in the majority of patients. In a small minority of
patients adequate relief without excessive adverse effects may depend
on the use of alternative opioids, spinal administration of analgesics or
non-drug methods of pain control. B
16. A small proportion of patients develop intolerable adverse effects with
oral morphine (in conjunction with a non-opioid and adjuvant analgesic as
appropriate) before achieving adequate pain relief. In such patients a
change to an alternative opioid or a change in the route of administration
should be considered. B
17. Hydromorphone or oxycodone, if available in both normal release and
modified release formulations for oral administration, are effective
alternatives to oral morphine. A
18. Methadone is an effective alternative but may be more complicated to use
compared with other opioids because of pronounced interindividual
differences in its plasma half-life, relative analgesic potency and duration
of action. Its use by non-specialist practitioners is not recommended. C
19. Transdermal fentanyl is an effective alternative to oral morphine but is
best reserved for patients whose opioid requirements are stable. It may
have particular advantages for such patients if they are unable to take
oral morphine, as an alternative to subcutaneous infusion. B
20. Spinal (epidural or intrathecal) administration of opioid analgesics 
in combination with local anaesthetics or clonidine should be considered
in patients who derive inadequate analgesia or suffer intolerable adverse
effects despite the optimal use of systemic opioids and 
non-opioids. B
Table 1 Morphine and alternative opioids in cancer painseverity so that the dose must be titrated against effect for each
patient, and the starting dose will be determined by previous anal-
gesic treatment. Patients changing from regular administration of a
step 2 opioid (in combination with a non-opioid) will usually 
start with 10 mg every 4 hours. If step 2 of the analgesic ladder 
is omitted 5 mg every 4 hours may suffice, whereas patients
converted from another step 3 opioid will require more. 
During dose titration it is preferable to use a formulation of
morphine that has a rapid onset and a short duration of action to
allow steady state to be achieved as quickly as possible. Normal
release formulations fulfil these requirements. Peak plasma
concentrations usually occur within the first hour after oral admin-
istration (Hoskin et al, 1989), with a reasonably rapid onset of
analgesia which then lasts for about 4 hours. In contrast modified
release morphine formulations produce a delayed peak plasma
concentration after 2–6 hours (Hoskin et al, 1989; Gourlay et al,
1997), the peak is attenuated (Hoskin et al, 1989), and analgesia
lasts for 12 or 24 hours (Hanks, 1990; Gourlay et al, 1997). This
means that with modified release morphine it is more difficult to
rapidly assess the adequacy of analgesia and to adjust the dose
during the dose-finding period. 
3. The simplest method of dose titration is with a dose
of normal release morphine given every 4 hours and
the same dose for breakthrough pain. This ‘rescue’
dose may be given as often as required (up to hourly)
and the total daily dose of morphine should be
reviewed daily. The regular dose can then be adjusted
to take into account the total amount of rescue
morphine C
The plasma elimination half-life of morphine is 2–4 hours (Glare
and Walsh, 1991) and steady state is achieved within 4–5 half-lives
(that is within 24 hours) (Säwe et al, 1983) after the start of treat-
ment and following dose adjustment. This is an important interval
in which to re-evaluate a patient and adjust the daily dose. This
method of dose titration avoids the need to remember 
predetermined increments and has been shown to be safe and
effective. 
During the dose titration phase using 4-hourly normal release
morphine, the full 4-hourly dose should be used for ‘rescue’. The
frequency with which the rescue dose can be offered depends on
the route of administration and the time to peak effect. Oral rescue
doses are usually offered up to every 1–2 hours and parenteral
doses (equivalent to the 4-hourly parenteral dose) can be offered as
frequently as every 15–30 minutes. 
4. If pain returns consistently before the next regular
dose is due the regular dose should be increased. In
general, normal release morphine does not need to be
given more often than every 4 hours and modified
release morphine more often than 12 or 24 hours
(according to the intended duration of the formulation).
Patients stabilized on regular oral morphine require
continued access to a rescue dose to treat
‘breakthrough’ pain  A
The drug regimen should be as simple as possible. Increasing the
frequency of administration may adversely affect compliance
and convenience for the patient. Increasing the dose allows a 4-
hourly or 12- or 24-hourly regimen to be achieved without
producing troublesome adverse effects associated with the
increase in peak blood concentrations (Hanks, 1990; Gourlay et
al, 1997). A few patients receiving 12-hourly formulations do not
seem to achieve a 12 hour duration of analgesia and require
administration every 8 hours. Occasionally patients taking a high
dose prefer dosing every 8 hours to avoid taking too many tablets
at a time, particularly in countries where no high-dose formula-
tions are available. 
Patients receiving regular oral opioids may experience acute
episodic breakthrough pain which may be a function of the pain
itself or may be precipitated by some voluntary act such as weight-
bearing or movement. There are no RCT data to establish the
appropriate dose of morphine for breakthrough pain and anecdotal
experience supports the use of doses varying from 30 to 100% of
the 4-hourly dose (Portenoy and Hagan, 1990). It may be that the
optimal dose for breakthrough pain can only be determined by
titration but we suggest that a simple approach is to use the equiv-
alent 4-hourly dose of morphine (as during the dose-finding
period). 
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Table 2 Strength and consistency of evidence supporting grades for each recommendation (as used by the Agency for Healthcare Policy and Research, USA)
A: requires at least one randomized controlled trial as part of a body of literature of overall good quality and consistency addressing the specific
recommendation (evidence levels Ia and Ib).
B: requires the availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendation (evidence levels Ila, 
Ilb and III).
C: requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of
directly applicable clinical studies of good quality (evidence level IV).
Category of evidence
Ia evidence from meta-analysis of randomised controlled trials.
Ib evidence from at least one randomised controlled trial.
IIa evidence from at least one controlled study without randomization.
IIb evidence from at least one other type of quasi-experimental study.
III evidence from non-experimental descriptive studies, such as comparative studies, correlation studies, and case-control studies.
IV evidence from expert committee reports or opinions or clinical experience of respected authorities, or both.5. Several countries do not have a normal release
formulation of morphine, though such a formulation is
necessary for optimal pain management. A different
strategy is needed if treatment is started with modified
release morphine. Changes to the regular dose should
not be made more frequently than every 48 hours, which
means that the dose titration phase will be prolonged  C
Total daily dose requirements should be estimated on the basis of
previous analgesic intake. Breakthrough pain is managed with
single doses of a non-opioid (non-steroidal anti-inflammatory drug
or paracetamol) as required, or with another short-lasting strong
opioid available for oral administration (such as oxycodone), or
with oral or rectal administration of morphine injection solution
(or a solution of morphine made from powder, if this is available
and cheaper). 
6. For patients receiving normal release morphine
every 4 hours, a double dose at bedtime is a simple
and effective way of avoiding being woken by pain  C
No formal investigations of this practice are available. However, it
has been widely adopted (Twycross, 1984) and does not seem to
cause problems (Regnard and Badger, 1987). 
7. Several modified release formulations are available.
There is no evidence that the 12-hourly formulations
(tablets, capsules or liquids) are substantially different
in their duration of effect and relative analgesic
potency. The same is true for the 24-hour formulations
though there is less evidence to draw on  A
Although in principle it is unwise to change between preparations
when using modified release products because of possible varia-
tions in release profiles and oral bioavailability there is no con-
sistent evidence that the various oral formulations of morphine
designed for administration every 12 hours have a different
pharmacokinetic or pharmacodynamic profile in patients (Collins
et al, 1998). 
Several once-a-day formulations of morphine have also been
developed. There are significant differences between some in their
pharmacokinetic profiles (Gourlay et al, 1997) but there is no
evidence that this is reflected in clinically significant differences
in patients: they appear to be equivalent in efficacy and in the
duration of effect. 
8. If patients are unable to take morphine orally the
preferred alternative route is subcutaneous. There is
generally no indication for giving morphine
intramuscularly for chronic cancer pain because
subcutaneous administration is simpler and less
painful C
The advantages of subcutaneous injection are that a smaller needle
is required, the chance of damage to nerves is less so that the site
of injection is not crucial, and the possibility of inadvertent intra-
venous injection is less because veins can be seen more easily.
Absorption is similar and peak plasma concentrations are achieved
within 15–30 minutes, with a more rapid onset of drug action than
after oral administration. 
Alternative drugs, particularly diamorphine (Twycross, 1994)
(in the UK) and hydromorphone (Moulin et al, 1991), may be
preferred for parenteral administration because they are more
soluble than morphine so that a smaller volume injection is
necessary. Transdermal fentanyl may be a useful non-invasive
alternative in patients with stable opioid requirements. 
Rectal administration may be preferred by some patients. The
bioavailability of morphine and duration of effect is similar to the
oral route and the equianalgesic dose by oral and rectal routes is
the same (Ripamonti and Bruera, 1991). 
9. The average relative potency ratio of oral morphine
to subcutaneous morphine is between 1:2 and 1:3
(i.e. 20–30 mg of morphine by mouth is equianalgesic
to 10 mg by s.c. injection)  C
Drugs administered by parenteral routes do not undergo pre-
systemic (‘first pass’) metabolism. The relative potency ratio of
oral to parenteral morphine has been highly controversial (Hanks
et al, 1987; Kaiko, 1988; Twycross, 1988). It seems that relative
potency varies according to the circumstances in which
morphine is used and between individual patients. When
converting from oral morphine to subcutaneous morphine, the
dose should be divided by three to get a roughly equianalgesic
effect, but upward or downward adjustment of the dose may then
be required. 
10. In patients requiring continuous parenteral
morphine, the preferred method of administration is by
subcutaneous infusion  C
Portable battery-operated syringe drivers are now widely used to
administer drugs by continuous slow infusion to patients with
advanced cancer who are unable to take oral medication (Dover,
1987). 
11. Intravenous infusion of morphine may be 
preferred in patients: a. who already have an in-
dwelling intravenous line; b. with generalized oedema;
c. who develop erythema, soreness or sterile
abscesses with subcutaneous administration; d. with
coagulation disorders; e. with poor peripheral
circulation C
Subcutaneous infusions have several advantages over intravenous
infusions: venous access is not required, close supervision is
unnecessary, and infection is unlikely. However, intravenous infu-
sion may have advantages in the specific circumstances listed
above. 
Transdermal fentanyl may be a useful non-invasive alternative
in patients with stable opioid requirements. 
12. The average relative potency ratio of oral to
intravenous morphine is between 1:2 and 1:3  A
The relative potency by intravenous and subcutaneous routes is the
same. When converting from oral to intravenous morphine the oral
dose should be divided by three (Kalso and Vainio, 1990). 
590 GW Hanks et al
British Journal of Cancer (2001) 84(5), 587–593 © 2001 Cancer Research Campaign13. The buccal, sublingual and nebulized routes of
administration of morphine are not recommended
because at the present time there is no evidence of
clinical advantage over the conventional routes  B
The absorption of morphine by these routes is unpredictable
(Chrubasik et al, 1988; Ripamonti and Bruera, 1991), and they are
best avoided for this drug. In contrast, the highly lipophilic drugs
methadone, fentanyl and buprenorphine are well absorbed sub-
lingually and buprenorphine is used by this route. Sublingual
buprenorphine may be a useful alternative to low-dose oral
morphine for patients who have difficulty swallowing, but experi-
ence of long-term use in cancer pain is limited. 
14. Oral transmucosal fentanyl citrate (OTFC) is an
effective treatment for ‘breakthrough pain’ in patients
stabilized on regular oral morphine or an alternative
step 3 opioid  A
OTFC produces a rapid onset of analgesia in 5–15 minutes
with a short duration of action of about 2 hours. This is a new
treatment with which there is very limited clinical experience
but good RCT data to support efficacy (Portenoy et al, 1991).
More safety data are required from wider and longer term clin-
ical use. 
15. Successful pain management with opioids requires
that adequate analgesia be achieved without excessive
adverse effects. By these criteria the application of the
WHO and the EAPC guidelines (using morphine as the
preferred step 3 opioid) permit effective control of
chronic cancer pain in the majority of patients. In a
small minority of patients adequate relief without
excessive adverse effects may depend on the use of
alternative opioids, spinal administration of analgesics
or non-drug methods of pain control  B
A number of observational studies have been carried out to val-
idate the WHO approach and have involved some 8000 patients in
different countries and different clinical environments (Jadad and
Browman, 1995; Mercadante, 1999). Reported response rates (for
adequate analgesia) have varied between 71 and 100% 
16. A small proportion of patients develop intolerable
adverse effects with oral morphine (in conjunction with
a non-opioid and adjuvant analgesic as appropriate)
before achieving adequate pain relief. In such patients
a change to an alternative opioid or a change in the
route of administration should be considered  B
In some patients experiencing troublesome adverse effects a
reduction in dose of morphine may alleviate these effects while
maintaining adequate analgesia (Hanks, 1991). If this is unsuc-
cessful switching to an alternative opioid agonist may allow titra-
tion to adequate analgesia without the same disabling effects. 
Dose-limiting adverse effects most often involve CNS toxicity
(drowsiness, cognitive impairment, confusion, hallucinations,
myoclonic jerks). In some centres it has been found necessary or
beneficial to change to an alternative opioid in up to 40% of
patients (de Stoutz et al, 1995). Sometimes several changes of drug
are employed and the term ‘opioid rotation’ has been coined to
describe this practice. Others estimate that the proportion of
patients who develop intolerable adverse effects with oral
morphine is much smaller. 
Switching between opioids complicates pain management and
this is a disadvantage for non-specialists (for whom it is not
recommended without expert advice). Appropriate strategies for
the management of this situation are the subject of a separate
expert report (Expert Working Group of the EAPC, in press). 
17. Hydromorphone or oxycodone, if available in both
normal release and modified release formulations for
oral administration, are effective alternatives to oral
morphine A
Hydromorphone is a semi-synthetic congener of morphine and a
potent m-selective agonist similar to morphine and between 5 and
10 times as potent (Houde, 1986). There appear to be no major
differences between hydromorphone and morphine in terms of
efficacy and adverse effects when used in equianalgesic doses. 
Oxycodone is a semi-synthetic congener of morphine which
until recently was most often prescribed in low-dose combination
products (with a non-opioid) for oral administration or as a rectal
suppository. In some countries it has been more widely used as a
single agent to treat post-operative pain and cancer pain. It has
now become available in new oral formulations (normal and
modified release). Oxycodone is similar to morphine in terms of
analgesia and adverse effects (Kalso and Vainio, 1990; Hanks and
Hawkins, 2000). Because of its better systemic availability (about
60–90%) the equianalgesic dose of oral oxycodone is between half
and two-thirds that of oral morphine (Bruera et al, 1998). 
18. Methadone is an effective alternative but may be
more complicated to use compared with other opioids
because of pronounced interindividual differences in
its plasma half-life, relative analgesic potency and
duration of action. Its use by non-specialist
practitioners is not recommended  C
Methadone is a synthetic opioid widely available in oral formula-
tions. It has no known active metabolites. There is a discrepancy
between the duration of its initial analgesic effect (4–6 hours) and
its plasma elimination half-life which averages approximately 24
hours with a range of 17 to over 100 hours (Plummer et al, 1988).
The drug accumulates on chronic dosing so that it should not be
given more frequently than 8-hourly (DeConno et al, 1996) to
avoid potential adverse effects. When switching from another
opioid it is often difficult to accurately determine the equianalgesic
dose (Ripamonti et al, 1998), particularly in patients tolerant to
high doses of opioids. 
19. Transdermal fentanyl is an effective alternative to
oral morphine but is best reserved for patients whose
opioid requirements are stable. It may have particular
advantages for such patients if they are unable to take
oral morphine, as an alternative to subcutaneous
infusion B
Fentanyl is a semi-synthetic opioid and an established intravenous
anaesthetic and analgesic drug which is about 80 times as potent as
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undergoes extensive first-pass metabolism. The low molecular
weight and high lipid solubility of fentanyl facilitate absorption
through the skin. After application fentanyl is undetectable in the
systemic circulation for 1 to 2 hours, but then serum levels rise
with analgesic effects evident within 8 to 16 hours and steady state
is achieved at 72 hours (Lehmann and Zech, 1992). Each patch
is applied for 3 days. An intradermal depot develops so that
following removal of the patch serum levels take about 16 hours to
drop to 50%. 
Transdermal fentanyl is effective and well tolerated in the
management of cancer pain, but is generally less flexible than
shorter-acting preparations. Although the 3 day duration of action
is an important advantage for patients with stable opioid require-
ments it can complicate management of patients with unstable
pain whose opioid requirements are fluctuating. There is some
experimental and clinical evidence that transdermal fentanyl is
associated with less constipation than morphine (Megens et al,
1998). 
20. Spinal (epidural or intrathecal) administration of
opioid analgesics in combination with local
anaesthetics or clonidine should be considered in
patients who derive inadequate analgesia or suffer
intolerable adverse effects despite the optimal use of
systemic opioids and non-opioids  B
Spinal opioids (± a local anaesthetic or clonidine) are indicated in
patients who have intolerable adverse effects with systemically
administered opioids. The addition (by the epidural route) 
of a local anaesthetic may be particularly useful in managing 
movement-related, incident pain (Mercadante, 1999b), and of
clonidine for neuropathic pain (Eisenach et al, 1995). 
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